Published in Pharma Investments, Ventures and Law Weekly, October 1st, 2006
Oxycyte administration increased oxygen tension over baseline in all eight evaluable trial patients.
The company expects to announce results of preliminary data analysis from this trial in the 4th quarter.
The primary purpose of the Phase IIa study is to demonstrate Oxycyte's ability to increase brain oxygen tension and favorably affect other brain chemistries that impact clinical outcome in patients suffering from severe head injury. The safety of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.